作者:Oscar A. Shepperson、Alan J. Cameron、Carol J. Wang、Paul W. R. Harris、John A. Taylor、Margaret A. Brimble
DOI:10.1039/d0ob01997f
日期:——
myristoylated 47-mer peptide mimic of the preS1 domain of the Hepatitis B virion, was identified as a potent protein–protein interaction (PPI) inhibitor blocking HBV fusion (IC50 = 140 pM). Herein we report an optimised chemical synthesis of Myrcludex B and a series of novel analogues. Employing a small modification to the Cysteine Lipidation of a Peptide or Amino acid (CLipPA) thiol–ene reaction, a library
尽管为治疗乙型肝炎病毒(HBV)做出了巨大努力,但迄今为止,长期的治疗方法还没有引起科学家的重视。最近,牛磺胆酸钠共转运多肽(NTCP)受体已被确定为HBV进入肝细胞的进入途径。Myrcludex B是乙型肝炎病毒粒子preS1结构域的N端肉豆蔻酰化的47-mer肽模拟物,被认为是阻断HBV融合的有效蛋白-蛋白相互作用(PPI)抑制剂(IC 50 = 140 pM)。本文中,我们报告了Myrcludex B和一系列新型类似物的优化化学合成。采用一个小的修改到一个肽或氨基酸的半胱氨酸脂质化(CLipPA)硫醇-烯反应,库小号制备了脂化的Myrcludex B和截短的(21-mer)类似物,为探索发现新的抗HBV肽提供了新的化学空间。该小号-lipidated类似物表现出相当或略有下降(〜2倍)的结合效力NTCP表达肝细胞相比Myrcludex B.三小号-lipidated类似物是高度有效的HBV抑制剂(IC